147.82 USD
▼-1.58-1.06%
盘后 147.00 -0.55%
2026-11-19
市值
$20.09B
市盈率
7.78
EPS
19.29
股息率
—
52 周区间
146.51 – 479.79
成交量
2.15M
Beta
0.44
目标价
284.96
52W 低 146.5152W 高 479.79
价格走势
公司简介
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo...